These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 9170147)
1. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147 [TBL] [Abstract][Full Text] [Related]
2. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Yamazaki H; Inoue K; Shimada T Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436 [TBL] [Abstract][Full Text] [Related]
3. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
4. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220 [TBL] [Abstract][Full Text] [Related]
5. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079 [TBL] [Abstract][Full Text] [Related]
6. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Wester MR; Lasker JM; Johnson EF; Raucy JL Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382 [TBL] [Abstract][Full Text] [Related]
7. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Goldstein JA; Faletto MB; Romkes-Sparks M; Sullivan T; Kitareewan S; Raucy JL; Lasker JM; Ghanayem BI Biochemistry; 1994 Feb; 33(7):1743-52. PubMed ID: 8110777 [TBL] [Abstract][Full Text] [Related]
8. Allelic and functional variability of cytochrome P4502C9. Bhasker CR; Miners JO; Coulter S; Birkett DJ Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362 [TBL] [Abstract][Full Text] [Related]
9. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Gill HJ; Tjia JF; Kitteringham NR; Pirmohamed M; Back DJ; Park BK Pharmacogenetics; 1999 Feb; 9(1):43-53. PubMed ID: 10208642 [TBL] [Abstract][Full Text] [Related]
10. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918 [TBL] [Abstract][Full Text] [Related]
12. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Yamazaki H; Shimada T Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296 [TBL] [Abstract][Full Text] [Related]
13. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825 [TBL] [Abstract][Full Text] [Related]
14. [Genetic polymorphism of the CYP2C subfamily]. Chiba K Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458 [TBL] [Abstract][Full Text] [Related]
15. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. Venkatakrishnan K; von Moltke LL; Greenblatt DJ J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353 [TBL] [Abstract][Full Text] [Related]
16. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Miyazawa M; Shindo M; Shimada T Drug Metab Dispos; 2002 May; 30(5):602-7. PubMed ID: 11950794 [TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104 [TBL] [Abstract][Full Text] [Related]
18. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. Inoue K; Yamazaki H; Shimada T Xenobiotica; 1998 Apr; 28(4):403-11. PubMed ID: 9604303 [TBL] [Abstract][Full Text] [Related]
19. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9. Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260 [TBL] [Abstract][Full Text] [Related]
20. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. Gentile DM; Verhoeven CH; Shimada T; Back DJ J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]